Moreover, our study contributes to the growing body of evidence associating LRIG1 with glioma pathogenesis, corroborating previous research highlighting LRIG1’s inhibitory effects on EGFR expression and downstream signaling pathways. This evidence concerns the gene EGFR and central nervous system cancer.